Compositions Comprising Quinolone and Methods for Treating or Controlling Infections
Compositions for treating or controlling infections comprise a fluoroquinolone having Formulae I-VIII and have a pH in the range from about 3.5 to about 5.5 or from about 10.5 to about 12. Methods for treating or controlling such infection use such compositions. Such compositions and methods can deliver a higher amount of the fluoroquinolone to the affected site.
1 . A composition for treating or controlling an infection in a subject, the composition comprising a fluoroquinolone having Formula I or salts thereof, wherein the composition has a pH in a range from about 3.5 to about 5.5 or from about 10.5 to about 12, and the fluoroquinolone is present in an amount effective to treat or control the infection,
wherein R 1 is selected from the group consisting of hydrogen, unsubstituted lower alkyl groups, substituted lower alkyl groups, cycloalkyl groups, unsubstituted C 5 -C 24 aryl groups, substituted C 5 -C 24 aryl groups, unsubstituted C 5 -C 24 heteroaryl groups, substituted C 5 -C 24 heteroaryl groups, and groups that can be hydrolyzed in living bodies; R 2 is selected from the group consisting of hydrogen, unsubstituted amino group, and amino groups substituted with one or two lower alkyl groups; R 3 is selected from the group consisting of hydrogen, unsubstituted lower alkyl groups, substituted lower alkyl groups, cycloalkyl groups, unsubstituted lower alkoxy groups, substituted lower alkoxy groups, unsubstituted C 5 -C 24 aryl groups, substituted C 5 -C 24 aryl groups, unsubstituted C 5 -C 24 heteroaryl groups, substituted C 5 -C 24 heteroaryl groups, unsubstituted C 5 -C 24 aryloxy groups, substituted C 5 -C 24 aryloxy groups, unsubstituted C 5 -C 24 heteroaryloxy groups, substituted C 5 -C 24 heteroaryloxy groups, and groups that can be hydrolyzed in living bodies; X is selected from the group consisting of halogen atoms; Y is selected from the group consisting of CH 2 , O, S, SO, SO 2 , and NR 4 , wherein R 4 is selected from the group consisting of hydrogen, unsubstituted lower alkyl groups, substituted lower alkyl groups, and cycloalkyl groups; and Z is selected from the group consisting of oxygen and two hydrogen atoms; and wherein the composition is capable of inhibiting a growth or survival of mixed types of microorganisms causing said infection.
2 . The composition of claim 1 , wherein R 1 is selected from the group consisting of hydrogen, C 1 -C 5 substituted and unsubstituted alkyl groups, C 3 -C 10 cycloalkyl groups, C 6 -C 14 substituted and unsubstituted aryl groups, C 5 -C 14 substituted and unsubstituted heteroaryl groups, and groups that can be hydrolyzed in living bodies; R 2 is selected from the group consisting of unsubstituted amino group and amino groups substituted with one or two C 1 -C 5 alkyl groups; R 3 is selected from the group consisting of hydrogen, C 1 -C 5 substituted and unsubstituted alkyl groups, C 3 -C 10 cycloalkyl groups, C 1 -C 5 substituted and unsubstituted alkoxy groups, C 5 -C 14 substituted and unsubstituted aryl groups, C 5 -C 14 substituted and unsubstituted heteroaryl groups, and C 5 -C 14 substituted and unsubstituted aryloxy groups; and X is selected from the group consisting of Cl, F, and Br.
3 . The composition of claim 1 , wherein R 1 is selected from the group consisting of hydrogen, C 1 -C 5 substituted and unsubstituted alkyl groups and groups that can be hydrolyzed in living bodies; R 2 is selected from the group consisting of unsubstituted amino group and amino groups substituted with one or two C 1 -C 5 alkyl groups; R 3 is selected from the group consisting of C 3 -C 10 cycloalkyl groups; X is selected from the group consisting of Cl and F; Y comprises hydrogen; and Z comprises two hydrogen atoms.
4 . The composition of claim 1 , wherein the fluoroquinolone is present in a concentration from about 0.01 to about 1 percent by weight.
5 . The composition of claim 1 , further comprising an additional anti-infective agent is selected from the group consisting of antiviral agents, antifungal agents, antiprotozoal agents, antibacterial agents other than the fluoroquinolones having Formula I, and mixtures thereof.
6 . The composition of claim 1 , further comprising an anti-inflammatory agent.
7 . The composition of claim 6 , wherein said anti-inflammatory agent is selected from the group consisting of glucocorticosteroids, non-steroidal anti-inflammatory drugs, inhibitors of cytokine production, and mixtures thereof.
8 . The composition of claim 4 , wherein the fluoroquinolone has Formula IV.
9 . The composition of claim 6 , wherein the fluoroquinolone has Formula IV.
10 . The composition of claim 1 , comprising a single enantiomer of the fluoroquinolone having Formula I.
11 . The composition of claim 1 , wherein the fluoroquinolone has Formula VI.
12 . The composition of claim 1 , wherein the fluoroquinolone comprises a racemic mixture of a compound having Formula III.
13 . The composition of claim 4 , wherein the composition is in a form of a solution, cream, emulsion, suspension, ointment, or gel.
14 . The composition of claim 5 , further comprising a quinolone other than the fluoroquinolones having Formula I, and wherein the additional anti-infective agent is selected from the group consisting of antiviral agents, antifungal agents, antiprotozoal agents, and mixtures thereof.
15 . A composition for treating or controlling an infection in a subject, the composition comprising a fluoroquinolone having Formula I or salts thereof, wherein the composition has a pH in a range from about 3.5 to about 5.5 or from about 10.5 to about 12, and the fluoroquinolone is present at a concentration from about 0.01 to 1 percent by weight of the total composition.
16 . A method for treating or controlling an infection in a subject, the method comprising administering to a subject in need thereof, a composition comprising a fluoroquinolone having Formula I or salts thereof, wherein the composition has a pH in a range from about 3.5 to about 5.5 or from about 10.5 to about 12, and the fluoroquinolone is present in an amount effective to treat or control said infection,
wherein R 1 is selected from the group consisting of hydrogen, unsubstituted lower alkyl groups, substituted lower alkyl groups, cycloalkyl groups, unsubstituted C 5 -C 24 aryl groups, substituted C 5 -C 24 aryl groups, unsubstituted C 5 -C 24 heteroaryl groups, substituted C 5 -C 24 heteroaryl groups, and groups that can be hydrolyzed in living bodies; R 2 is selected from the group consisting of hydrogen, unsubstituted amino group, and amino groups substituted with one or two lower alkyl groups; R 3 is selected from the group consisting of hydrogen, unsubstituted lower alkyl groups, substituted lower alkyl groups, cycloalkyl groups, unsubstituted lower alkoxy groups, substituted lower alkoxy groups, unsubstituted C 5 -C 24 aryl groups, substituted C 5 -C 24 aryl groups, unsubstituted C 5 -C 24 heteroaryl groups, substituted C 5 -C 24 heteroaryl groups, unsubstituted C 5 -C 24 aryloxy groups, substituted C 5 -C 24 aryloxy groups, unsubstituted C 5 -C 24 heteroaryloxy groups, substituted C 5 -C 24 heteroaryloxy groups, and groups that can be hydrolyzed in living bodies; X is selected from the group consisting of halogen atoms; Y is selected from the group consisting of CH 2 , O, S, SO, SO 2 , and NR 4 , wherein R 4 is selected from the group consisting of hydrogen, unsubstituted lower alkyl groups, substituted lower alkyl groups, and cycloalkyl groups; and Z is selected from the group consisting of oxygen and two hydrogen atoms; and wherein the composition is capable of inhibiting a growth or survival of at least a bacterium causing said infection.
17 . The method of claim 16 , wherein the composition is administered topically, orally, or systemically.
18 . The method of claim 17 , wherein the composition is administered topically.
19 . The method of claim 18 , wherein the infection is an infection of an eye, an ear, a portion of a respiratory system, or a combination thereof.
20 . The method of claim 16 , wherein a microorganism causing the infection is a bacterium that is resistant to an antibacterial agent.
21 . The method of claim 16 , wherein the composition further comprises a quinolone other than the fluoroquinolones having Formula I, and wherein the additional anti-infective agent is selected from the group consisting of antiviral agents, antifungal agents, antiprotozoal agents, and mixtures thereof.
22 . A method for treating or controlling an infection in a subject, the method comprising administering to the subject in need thereof, a composition comprising: (a) a fluoroquinolone having Formula III or salts thereof; and (b) an additional anti-infective agent; wherein the composition has a pH in a range from about 3.5 to about 5.5 or from about 10.5 to about 12, and the fluoroquinolone has a concentration of from about 0.01 to about 1 percent by weight.
23 . The method of claim 22 , wherein the fluoroquinolone is a single enantiomer of the fluoroquinolone having Formula III.
24 . The method of claim 22 , wherein the composition is administered topically, orally, or systemically.
25 . The method of claim 22 , wherein the infection is an infection of an eye, an ear, a portion of a respiratory tract, or a combination thereof.